<DOC>
	<DOCNO>NCT01898663</DOCNO>
	<brief_summary>The aim Phase Ⅰ/Ⅱ study evaluate safety efficacy dendritic cell ( DCs ) vaccine combine cytokine-induced killer ( CIK ) cell patient high-risk soft tissue sarcoma . Experimental recombinant adenovirus-transfected DCs , engineer express MUC1 Survivin use DCs-based immunotherapy . Based result previously perform preclinical study DCs vaccine combine CIK cell , investigator plan perform clinical trial .</brief_summary>
	<brief_title>DCs Vaccine Combined With Cytokine-induced Killer Cells Patients With High-risk Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Intermediate high grade sarcoma determine pathology review Histopathologically confirm diagnosis intermediate high grade sarcoma Age≥18 year time consent KPS ( Karnofsky Performance Scale ) ≥70 Patient 's write informed consent No steroid therapy within 4 week first DC vaccination Stable disease , complete response partial response ( WHO , RECIST ) Predicted survival≥3 month Normal liver , kidney marrow function : WBC≥3.5×109/L、PLT≥90×109/L Hb≥90g/L ; blood Cr≤1.5×UNL ( upper normal limit ) blood BIL≤1.5×UNL ; ALT、AST≤1.5×UNL ALT/AST≤5.0×UNL Serious dysfunction vital organ ( heart , liver kidney ) Received organ transplantation Patients malignancy brain metastasis History autoimmune disease Pregnant breastfeed patient Active chronic infectious disease History allergy hypersensitivity study product excipients Currently participate another clinical trial Received chemotherapy , radiotherapy , immune inhibitor ( corticosteroid ) immunotherapy ( vaccine ) prior 4 week Unfit participate clinical trial investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>